Phentermine's Cardiovascular Effects

Mechanism of Action and Cardiovascular Effects

Phentermine is a sympathomimetic amine that works by increasing norepinephrine levels in the central nervous system, which directly affects cardiovascular function 1
As a norepinephrine reuptake inhibitor, phentermine can lead to both hyperadrenergic effects and paradoxical refractory hypotension during surgery 2

In the largest trial of phentermine-topiramate ER, patients showed reductions in systolic blood pressure averaging 4.7-5.6 mmHg compared to 2.4 mmHg in the placebo group 3
Diastolic blood pressure reductions were 3.4-3.8 mmHg in the treatment groups versus 2.7 mmHg in the placebo group 3

The American College of Cardiology and other guideline societies imply that phentermine is contraindicated in patients with a history of cardiovascular disease, uncontrolled hypertension, and patients taking monoamine oxidase inhibitors (or within 14 days of discontinuation) due to risk of hypertensive crisis 1

Blood pressure and heart rate should be monitored periodically during phentermine treatment, according to clinical guidelines 1
Consider starting at lower doses (4-8 mg) in patients with cardiac risk factors, as recommended by medical societies 1

The American Gastroenterological Association recommends discontinuing phentermine at least 4 days before procedures requiring anesthesia 3, 2
This is due to potential perioperative complications including hypertension, hypotension, bradycardia, and hyperthermia 3

There are currently no large cardiovascular outcome trials for long-term use of phentermine monotherapy, as noted by medical guideline societies 1
Phentermine is FDA-approved only for short-term use (≤12 weeks), though many clinicians use it off-label for longer periods 1

The American Diabetes Association and other guideline societies recommend monitoring blood pressure and heart rate closely, especially in the first 12 weeks after resumption of phentermine, due to the risk of cardiovascular complications 4
Patients should be assessed for cardiovascular complications given the stress of surgery and potential for unmasking cardiac disease, and consideration should be given to the patient's overall cardiovascular risk profile, with phentermine being avoided in patients with cardiovascular disease 5

The FDA approves phentermine only for short-term use (≤12 weeks), and the postoperative period provides an opportunity to reassess the need for continued phentermine therapy and consider alternative treatments with established cardiovascular safety profiles, such as GLP-1 receptor agonists 4, 5